August 2025

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the opportunities they present for patients and the potential challenges from a laboratory perspective.

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and beyond in patients with multiple myeloma.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed multiple myeloma.

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging in second-line RCC therapy.